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221 Does the use of a telehealth system, (I-neb Insight Online)
improve nebuliser adherence and reduce treatment times in
children with cystic ﬁbrosis?
C. Thornton1, N. Moss1. 1Royal Manchester Children’s Hospital, Therapy and
Dietetic Services, Manchester, United Kingdom
Aim: To compare self reported adherence and treatment times of nebulised therapy
against objective data obtained via download from the patient’s I-neb nebuliser
collected at 3 monthly visits. To subsequently monitor the affect of enrolling patients
on a new telehealth system designed to allow patients to obtain treatment related
feedback.
Methodology: Patients using I-nebs on a daily basis were asked questions regarding
their perceived adherence to therapy and length of treatments. Data downloaded
from their I-nebs enabled comparisons to be made between reported and actual
values. Consenting patients were then set up on a telehealth system (I-neb Insight
Online) to monitor the affect on adherence and treatment times.
Results: Data was obtained for 15 patients. 6 patients self reports were within 10%
of their actual adherence. 9 patients over reported their adherence (range 13−49%)
with an average of 36%.
Reported versus actual treatment times were compared for 9 patients. 7 patients
under estimated treatment times.
Patients that were subsequently enrolled onto Insight Online with <90% adherence
improved adherence over the proceeding 4 weeks by an average of 22% (range
9−59%). 4 out of 5 patients who had excessive treatment times (>5 minutes) reduced
treatment times by >90 seconds.
Conclusions: Patients self report of nebuliser adherence and treatment times can
be inaccurate providing little motivation to improve. Early indicators suggest there
is beneﬁt providing treatment related feedback at home using a system like Insight
Online for improving adherence and reducing treatment burden. This will allow
patients and physiotherapists to set goals which can be closely monitored.
222 Real life timing and cleaning of inhalation therapy
H. Parrott1, P. Agent1, D. Bilton1. 1Royal Brompton Hospital, Adult CF Unit,
London, United Kingdom
Advances in inhalation devices have resulted in greater efﬁciency in nebulisation
times than jet nebulisers. Patients often comment on the complexity, time and
cleaning of component parts.
Objectives: To evaluate nebuliser assembly, delivery and cleaning times for 3
systems used by adults with CF (PARI LC plus, eﬂow rapid, Ineb) and compliance
with recommended manufacturer’s cleaning and disinfection guidance.
Methods: 30 patients (n = 10 each device) were timed completing a single inhalation
for nebuliser assembly, delivery and cleaning and audited against a recommended
cleaning and disinfection checklist for their usual device in their own home. All
consumables were <30 days old.
Table: Inhalation and cleaning results
PARI LC plus
n = 10
eFlow rapid
n = 10
Ineb
n = 10
Mean assembly & inhalation time, min:s
(range)
9:52
(6:15−15:37)
6:26
(2:35−10:17)
5:12
(4:05−6:50)
Mean cleaning time, min:s (range) 1:26
(0:0−4:18)
1:12
(0:10−2:10)
2.01
(0:16−3:32)
Mean total time, min:s (range) 11:18
(6:35−19:55)
7:38
(3:52−10:47)
7:14
(5:36−10:22)
>50% recommended cleaning steps complete 70% 50% 80%
<50% recommended cleaning steps complete 30% 50% 20%
Disinfection as per manufacturer’s guide 0% 50% 40%
Conclusion: This audit was completed in the home to represent ‘real life’.
Inhalation and assembly times were very similar for the eﬂow rapid and Ineb and
quicker than the PARI LC plus. Immediate cleaning was brief but similar for all
devices but adequate rinsing was often omitted. The majority of patients dried
equipment correctly, however adherence to recommended disinfection procedures
was variable and poor. Methods to address adherence and improve cleaning practice
are required, as many drugs are still inhaled via nebulisers, despite the advent of
dry powder inhalers which require minimal cleaning and have low inhalation times.
223 Nebulised meropenem: A review of one year outcome in an adult
cystic ﬁbrosis centre
V. Kendall1, J. Parker-Stafford1, S. Johnson1, A.M. Jones1, A. Brennan1.
1University Hospital of South Manchester, MACFC, Manchester, United Kingdom
Background: Meropenem (Mero) is a broad spectrum carbapenem which has been
used to treat a wide range of infections. It remains unlicensed in its nebulised form,
but has shown to be well tolerated. (Carrolan 2012, Parker-Stafford 2011).
Objective: To evaluate tolerance and outcome of nebulised Mero over 1 year.
Methods: Records from March 2006-Jan 2012 of patients who had received
nebulised Mero were examined for indications, demographics, sputum microbiology,
lung function, tolerability and IV ABx days. Best FEV1% predicted and number
of IV ABx days 1 year pre and post challenge were analysed.
Results: 39 patients median (range) age 29 (16−44) years with a predicted
FEV1% = 35% (11−86). Chronically infected with B.cep (n = 18), Ps.A (n = 18)
or non Ps.A (n = 3) and clinically unstable on standard maintenance nebulised
antibiotic therapy.
31% (n = 13) discontinued Mero within 1 year; 8% (n = 3) due to subjective tightness
and 3% (n = 1) dysgeusia. 10% (n = 4) died and 10% (n = 4) were transplanted. Of
the remaining 69% (n = 26) continued for >1 year, other side effects included 31%
(n = 12) improved expectoration 10% (n = 4) throat irritation/tightness, 10% (n = 4)
teeth discoloration and 3% (n = 1) wheeze, none of which caused discontinuation.
FEV1% predicted 1 year pre Mero = 46.5% (26−92), post = 42.0% (20–100). IV
days 1 year pre Mero = 48.5 (0–132), post = 40.0 (0–193). There was no signiﬁcant
difference in lung function or IV days.
Conclusion: Nebulised Mero was commenced with patients within different sputum
microbiological groups who were clinically declining despite conventional nebulised
therapy. It was well tolerated by the majority and lung function remained stable on
treatment.
224 Adherence to the administration of aerosolized promixin with the
I-neb adaptive aerosol delivery (AAD) system, lung function and
administration times in patients with cystic ﬁbrosis (CF)
M. Dona`1, F. Alatri2, A. Brivio3, G. Mamprin1, M. Barbisan1, M. Varchetta2,
S. De Sanctis2, S. Gambazza3, S. Karapanagiotis3, M. Ros1. 1Ospedale S.
Maria di Ca` Foncello, Cystic Fibrosis, Treviso, Italy; 2Policlinico Umberto I,
Cystic Fibrosis, Rome, Italy; 3IRCCS Fondazione Ca` Granda, Ospedale Maggiore
Policlinico Milano, Cystic Fibrosis, Milan, Italy
Background: Daily and regular administration of prescribed therapies is crucial for
patients’ well-being. I-Neb Respironics® allows to record and analyze information
about adherence and compliance thus ensuring an objective and reproducible
evaluation.
Aim: To evaluate retrospectively the adherence to inhaled colistimethate sodium
during the ﬁrst year of use and the overall functioning of the I-neb system.
Methods: CF patients with Pseudomonas aeruginosa chronic infection aged 6 yrs
or more were recruited from 3 Italian CF centers. All patients were treated through
the I-neb system and had to be trained to its proper use.
Results: 41 patients analyzed (mean age 21.4, FEV1 75.5% pred., BMI 19.4) spent
115 minutes daily on physiotherapy. Treatment lasted 8.6 months with mean 496
administrations delivered in mean 5.6 minutes. Timing between administrations
was 12.17 hrs, mean doses missing 2.5 and the incomplete or void dose was 0.9.
Physiotherapy treatment burden and missed doses (r 0.8080, p< 0.0001), average
duration and problems of incomplete or void doses (r 0.444, p = 0.0038) were found
signiﬁcantly correlated. In the pediatric population (n = 20) there was a signiﬁcative
correlation between age and treatment time (r −0.750, p< 0.0001) while adults
showed a signiﬁcative correlation between the treatment time and lung function
(r −0.610, p = 0.0015). In patients treated continuously, time decreased from 6.9 to
4.7 minutes (p = 0.009).
Conclusions: I-neb device allowed patients to achieve good adherence to therapy
in short administration time. Downloading data at a distance to early detect patients
poorly trained, changes in adherence or technical issues might be challenging.
